Register Now: Beyond EDC: Designing a Connected Data Strategy for Predictive Clinical Development
News|Articles|February 21, 2024

Worldwide Clinical Trials Expands Clinical Pharmacology Unit

Upgrades include end-of-life equipment replacements and relocation.

Worldwide Clinical Trials has announced an expansion of the pharmacy at its Clinical Pharmacology Unit (CPU) in San Antonio, Texas, according to a company press release.1 In addition to equipment upgrades, expansion efforts focused on operational demand, workplace demand, and employee engagement with the overall goal of enhancing customer experience. Completed in January 2024, the expanded pharmacy provides customers with streamlined processes, as well as decreased timelines and costs.

“A common thread among our Worldwide team members is a passion to take care of our customers—we’re always looking for ways to improve our partnerships,” said Mike Mencer, executive vice president and general manager, early phase, Worldwide Clinical Trials in the press release. “As part of an ongoing $5 million upgrade to our CPU, this expansion aligns with our culture of quality and our dedication to continuous improvement and innovation to meet our customers’ growing needs as we work together to improve the lives of patients around the world.”

Worldwide’s CPU, a 200-bed, fit-for-purpose facility, has been in operation since 2005. Within the unit, studies are conducted in healthy volunteers, patients, and specialty populations. The CPU is conveniently located one hour from Worldwide’s Bioanalytical Center of Excellence, offering an approach that benefits customers through streamlined vendor management, consistent standards, technical expertise, and overall efficiencies such as sample transfer and rapid processing.

“Expanding our pharmacy in size enables us to expand in volume, providing additional opportunities and efficiencies for our customers,” said Lona Sheeran, senior vice president, clinical operations, early phase, Worldwide Clinical Trials in the press release. “We can now manufacture onsite, in real time, for Phase I studies per FDA guidance, allowing our customers the option to pivot on their dose while their study is ongoing. This service is unique and can save our customers thousands of dollars and months of time—a huge advantage in this fast-paced industry.”

Reference

  1. Worldwide Clinical Trials Expands Clinical Pharmacology Unit Pharmacy to Enhance Customer Experience; Adds Efficiencies and Decreases Timelines. News release. February 21, 2024. Accessed February 21, 2024. https://www.businesswire.com/news/home/20240221954891/en


Related to this article

© Grispb - © Grispb - stock.adobe.com
Mistral and OpenAI produced identical overall eligibility labels across 200 synthetic patient-study assessments, with criterion-level disagreements concentrated in inclusion criteria where models switch between “Uncertain” and “Not included” when records lack sufficient evidence, so model choice should be driven by deployment architecture, control, and cost rather than assumed interchangeability.
The Human Side of Clinical Trials: Before Burden Becomes Risk, Capturing Friction in Real Time
In Episode 4 of The Human Side of Clinical Trials, host Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., speaks with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about how capturing friction closer to the moment it happens can reveal unclear instructions, technology friction, and workarounds that retrospective surveys and debriefs tend to miss.